

# WHO consolidated guidelines on tuberculosis

Module 1: Prevention

**Tuberculosis preventive treatment**



World Health  
Organization

WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment

ISBN 978-92-4-000150-3 (electronic version)

ISBN 978-92-4-000151-0 (print version)

ISBN 978-92-4-000267-8 (epub)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design by Inis Communication

# WHO consolidated guidelines on tuberculosis

Module 1: Prevention

**Tuberculosis preventive treatment**



# Table of Contents

Acknowledgements.....	iv
Abbreviations & acronyms.....	vi
Definitions.....	vii
Executive summary.....	viii
Introduction.....	1
1. Recommendations.....	3
2. Monitoring and evaluation.....	26
3. Research gaps.....	28
4. References.....	31
Supplementary Table.....	38

## Online annexes

- Annex 1. Methods and Expert panels
- Annex 2. GRADE Summary of Evidence Tables
- Annex 3. GRADE Evidence to Decision Tables

# Acknowledgements

The production of the *WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment* was coordinated and written by Dennis Falzon, Avinash Kanchar and Matteo Zignol under the overall direction of Tereza Kasaeva, Director of the WHO Global TB Programme. The WHO Global TB Programme gratefully acknowledges the contribution of all experts involved in the production of these guidelines.<sup>1</sup>

## Guideline Development Group

The Guideline Development Group (GDG) was composed of Mohammed Al Lawati (Consultant Physician, Oman); Helen Ayles (Infectious Diseases and International Health, LSHTM, Lusaka, Zambia); Rolando Cedillos (Service of Infectious Diseases and Integrated Programme for STI/HIV/AIDS, El Salvador); Padmapriyadarsini Chandrasekaran (National Institute for Research in Tuberculosis, India); Diana Gibb (Medical Research Council, United Kingdom of Great Britain and Northern Ireland (UK)); Yohhei Hamada (Research Institute of Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA), Japan); Anthony D Harries (International Union Against Tuberculosis and Lung Disease, Paris, France; London School of Hygiene and Tropical Medicine, London, UK); Alexander Kay (Baylor College of Medicine, Global TB Program, Eswatini); Nasehi Mahshid (Department of TB and Leprosy Control, Centre for Control of Communicable Diseases, Ministry of Health and Medical Education, Iran); Alberto Matteelli (University of Brescia, WHO Collaborating Centre for TB/HIV and TB Elimination, Italy); Lindiwe Mvusi (National Department of Health, South Africa); Kuldeep Singh Sachdeva (National Tuberculosis Elimination Programme, India); Nandi Siegfried (Medical Research Council / University of Cape Town, South Africa); Ezio Távorá dos Santos Filho (Civil Society Task Force, Brazil); Marieke van der Werf (European Centre for Disease Prevention and Control, Sweden); Wim Vandeveld (Global TB Community Advisory Board, South Africa); and Irina Vasilyeva (Ministry of Health, Russian Federation). The co-chairs of the GDG were Lindiwe Mvusi and Nandi Siegfried. Dr Siegfried was also the GRADE methodologist

## External Reviewers

The External Review Group (ERG) was composed of Connie Erkens (KNCV TB Foundation, Netherlands); Steve Graham (Center for International Child Health University of Melbourne, Australia); Giovanni B. Migliori (Istituti Clinici Scientifici Maugeri, IRCCS and WHO Collaborating Centre for TB and Lung Diseases, Italy); Rohit Sarin (National Institute of TB and Respiratory Diseases, India); James Seddon (Imperial College, UK); Alena Skrahina (Republican Scientific and Practical Centre for Pulmonology and TB, Belarus); and Carrie Tudor (International Council of Nurses, South Africa). Edits to the draft guidelines were also provided by people who responded to the call for public review on 1 July 2019.

## Evidence reviewers

The following persons contributed to the reviews and summarization of evidence for the guidelines:

Mayara Bastos, Jonathon Campbell and Richard (Dick) Menzies (McGill University, Canada) provided the first draft of estimates and footnotes for the GRADE summary of evidence table from the trials of four months of daily rifampicin (PICO 6).

---

<sup>1</sup> More information on the areas of expertise, gender and geographical distribution, declarations of interests and the management of potential conflict for members of the GDG and ERG are summarised in **Annex 1** (online).

Richard Chaisson and Ritesh Ramchandani (Johns Hopkins University, USA) and Susan Swindells (University of Nebraska Medical Center, USA) provided the first draft of estimates and footnotes for the GRADE summary of evidence table from the BRIEF-TB/A5279 trial of one month of daily rifapentine and isoniazid (PICO 7).

Yohhei Hamada (RIT/JATA, Japan) researched and wrote the report on the systematic review and meta-analysis of the safety of isoniazid preventive treatment in pregnancy (PICO 9), with support from Carmen Figueroa (WHO Global TB Programme), and Mario Sánchez (WHO Management of Non-communicable Diseases, Disability, Violence & Injury Prevention). Lynne M. Mofenson (Consultant, WHO HIV Department) contributed with a qualitative review of the safety of isoniazid in pregnancy. Amita Gupta and Nicole Salazar-Austin (Johns Hopkins University, USA) provided unpublished information from their studies to complete the evidence review.

### **WHO Guideline Steering Group**

The WHO Guideline Steering Group was composed of Annabel Baddeley, Annemieke Brands, Dennis Falzon, Carmen Figueroa, Medea Gegia, Christopher Gilpin, Philippe Glaziou, Avinash Kanchar and Matteo Zignol from the WHO Global TB Programme; Françoise Renaud and Satvinder Singh from the WHO Department of HIV/AIDS; Andreas Reis from the Department of Information, Evidence and Research; and Lorenzo Moja from the Department of Essential Medicines and Health Products. Wilson Were from the WHO Department of Maternal, Newborn, Child and Adolescent Health also reviewed the guidelines.

### **Others**

The following persons participated as observers at the GDG meetings: Sevim Ahmedov (US Agency for International Development (USAID), USA); Draurio Barreira Cravo Neto (UNITAID, Switzerland); Anand Date (Centers for Disease Control and Prevention, USA); Lucia Gonzalez Fernandez (International AIDS Society, Switzerland); Harry Hausler (TBHIV Care, South Africa); Cecily Miller (University of California San Francisco, USA); Surbhi Modi (Centers for Disease Control and Prevention, USA); Suvanand Sahu (Stop TB Partnership, Switzerland); Anna Scardigli (Global Fund to Fight AIDS, TB and Malaria, Switzerland).

WHO acknowledges the contribution of the Guideline Review Committee and its WHO secretariat in reviewing and approving the guidelines ahead of their publication.

Funding for the guidelines update in 2019–2020 derived from WHO grants provided by USAID and the Russian Federation.

# Abbreviations & acronyms

<b>1HP</b>	One month of daily rifapentine plus isoniazid
<b>3HP</b>	Three months of weekly rifapentine plus isoniazid
<b>3HR</b>	Three months of daily rifampicin plus isoniazid
<b>4R</b>	Four months of daily rifampicin monotherapy
<b>6H</b>	Six months of daily isoniazid monotherapy
<b>9H</b>	Nine months of daily isoniazid monotherapy
<b>ART</b>	antiretroviral treatment
<b>BCG</b>	bacille Calmette-Guérin (vaccine)
<b>CI</b>	confidence interval
<b>ERG</b>	External Review Group
<b>GDG</b>	Guideline Development Group
<b>GRADE</b>	grading of recommendations assessment, development and evaluation
<b>HIV</b>	human immunodeficiency virus
<b>Hr-TB</b>	isoniazid-resistant, rifampicin-susceptible TB
<b>IGRA</b>	interferon-gamma release assay
<b>IPT</b>	isoniazid preventive treatment (or monotherapy)
<b>LTBI</b>	latent tuberculosis infection
<b>MDR-TB</b>	multidrug-resistant tuberculosis
<b>mITT</b>	modified intention to treat (population)
<b>OR</b>	odds ratio
<b>PICO</b>	population, intervention, comparator and outcomes
<b>PLHIV</b>	people living with HIV
<b>PMTPT</b>	programmatic management of tuberculosis preventive treatment
<b>RCT</b>	randomized controlled trial

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24749](https://www.yunbaogao.cn/report/index/report?reportId=5_24749)

